CN103520200B - Compositions containing MDG-1 polysaccharide of lilyturf root-1 and improve the application in the medicine of metabolic syndrome or health product in preparation - Google Patents
Compositions containing MDG-1 polysaccharide of lilyturf root-1 and improve the application in the medicine of metabolic syndrome or health product in preparation Download PDFInfo
- Publication number
- CN103520200B CN103520200B CN201310437140.0A CN201310437140A CN103520200B CN 103520200 B CN103520200 B CN 103520200B CN 201310437140 A CN201310437140 A CN 201310437140A CN 103520200 B CN103520200 B CN 103520200B
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- mdg
- lilyturf root
- radix ophiopogonis
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a kind of compositions containing MDG-1 polysaccharide of lilyturf root-1 and improve the application in the medicine of metabolic syndrome or health product in preparation, it is mainly made up of the raw material of following weight portion: MDG-1 polysaccharide of lilyturf root-1 15-85 part, oligomeric xylose 15-85 part, it can be prepared into any one and commonly use oral formulations.In MDG-1 polysaccharide of lilyturf root-1 compositions of the present invention, MDG-1 polysaccharide of lilyturf root-1 molecular weight is below 10000 dalton, oligomeric xylose is commercially available, and said composition has adjustment metabolic syndrome patients enteric flora disturbance, blood sugar lowering, blood fat reducing and improves the functions such as insulin resistant thus improve metabolic syndrome patients's symptom.
Description
Technical field
The present invention relates to a kind of compositions, particularly relate to a kind of compositions containing MDG-1 polysaccharide of lilyturf root-1; In addition, the invention still further relates to the novelty teabag that this contains the compositions of MDG-1 polysaccharide of lilyturf root-1, particularly relate to this compositions containing MDG-1 polysaccharide of lilyturf root-1 and preparing the application in the medicine or health product improving metabolic syndrome.
Background technology
Metabolic syndrome (metabolic syndrome) refers to the clustering phenomena of the cardiovascular risk factor of physiological metabolism aspect, these risk factor mainly comprise metabolism obstacles of blood glucose (impaired fasting glucose (IFG), impaired glucose tolerance, type Ⅱdiabetes mellitus), Anomalous lipid metablism (rising of blood triglyceride concentration, Very Low Density Lipoprotein Concentration rising, High-density Lipoprotein-cholesterol reduce), hypertension, central obesity etc.
People is had the sixties in 20th century impaired glucose tolerance and hypertension to be called " rich syndrome ".Within 1989, there is people again by using the Abdominal obesity based on hyperinsulinemia, impaired glucose tolerance, hypertriglyceridemia, hypertension as the risk factor of coronary heart disease, be summarised as " dead quartet ".Within 1991, there is again people by this group metabolic-cardiovascular disease syndrome called after " insuline resistance syndrome ".Until the World Health Organization (WHO) in 1998 Committee of Experts discusses this syndrome specially, recommendation " metabolic syndrome " is named.
Metabolic syndrome is mainly in modern civilization society, diagnoses syndrome patients for this reason to account for the 20%-40% of person in middle and old age's population.The prevalence of northern China resident, higher than south, is respectively 23.3% and 11.5%, and urbanite, higher than urban residents, is respectively 23.5% and 14.7%.Along with the growth at growth in the living standard, age, the prevalence of metabolic syndrome increases gradually.
The prophylactico-therapeutic measures of metabolic syndrome focuses on early intervention.First using diet control and exercise therapy as the long-term basic measure intervened, then being aided with suitable medicine or health product to reducing blood glucose, correcting blood fat disorder.
The dried root of system Liliaceae Radix Ophiopogonis perennial Ophiopogon plant Radix Ophiopogonis, is called for short Radix Ophiopogonis.There is YIN nourishing and the production of body fluid promoting, effect that lung moistening clears away heart-fire, clinically for diseases such as consumption of body fluid caused by febrile disease, restlessness and thirst, dryness of the lung dry cough.The diabetes traditional Chinese medical science is called it and " is quenched one's thirst ", and differentiation of symptoms and signs for classification of syndrome is generally divided into intense heat due to deficiency of YIN, deficiency of both QI and YIN and deficiency of both YIN and YANG etc., and treat with nourshing Yin and drynsessmoistening prescription, tonifying speen and tonifying kidney is main.Radix Ophiopogonis is conventional YIN nourishing Chinese medicine, has the function that yin nourishing of promoting the production of body fluid, clearing heat and moistening dryness, relieving restlessness are quenched one's thirst, and sayed as " book on Chinese herbal medicine justice ": " Radix Ophiopogonis Han Run, yin nourishing is quenched one's thirst, and is all the medicine that must use ".Therefore, the treatment of diabetes is also used to clinically Radix Ophiopogonis.Early stage, pharmacological research found; MDG-1 polysaccharide of lilyturf root-1 may Radix Ophiopogonis blood sugar lowering, blood fat reducing, improve in insulin resistant (the Xu J that plays an important role; Wang Y; et al.Hypoglycemic effects of MDG-1; a polysaccharide derived from Ophiopogon japonicus; in the ob/ob mouse model of type2diabetes mellitus.International Journal of Biological Macromolecules, 2011 (49): 657-662.; Ling-Yi Wang, Yuan Wang, et al.MDG-1, a polysaccharide from Ophiopogon japonicus exerts hypoglycemic effects through PI3K/Akt pathway in a diabetic KKAy mouse model.Journal of Ethnopharmacology.2012 (143): 347-354).Meanwhile, because in metabolic syndrome patients's body, function of intestinal canal easily gets muddled, cause probiotic bacteria and pathogen proportional imbalance in patient body.Therefore, suitable prebiotic-supplemented material is to recovery Intestinal Mucosal Injury in Patients Undergoing balance, and maintaining body homergy balance has important effect.
MDG-1 polysaccharide of lilyturf root-1 is β-D type levan, early-stage Study shows the activity (Wang Lingyi having propagation probiotic bacteria, suppress growth of pathogenic bacteria, Wang Yuan, Deng the impact [J] on non-diabetic mice carbohydrate tolerance and intestinal microbial population of. MDG-1 polysaccharide of lilyturf root-1. Chinese Journal of New Drugs and Clinical Remedies, 2011,30 (6): 453-457).Oligomeric xylose (xylo-oligosaccharide, XO) is the plant (as corn cob, bagasse, cottonseed sugar, Testa Tritici, birch etc.) of being rich in xylan is raw material, by xylanase hydrolysis, and separation and purification and the class non-digestible oligosaccharide obtained.Generally be combined into β-Isosorbide-5-Nitrae glycosidic bond by 2-7 xylose molecule, stable in physicochemical property, has the function of very strong propagation beneficial bacteria of intestinal tract.
There is no in prior art with MDG-1 polysaccharide of lilyturf root-1 and oligomeric xylose mixing, by regulating intestinal canal Bacterial community, blood sugar lowering, blood fat reducing, improve the technology that insulin resistant isoreactivity improves metabolic syndrome symptom.
Summary of the invention
One of the technical problem to be solved in the present invention is to provide a kind of compositions containing MDG-1 polysaccharide of lilyturf root-1.
One of the technical problem to be solved in the present invention is the application providing above-mentioned composition, its by regulating intestinal canal Bacterial community to reach blood sugar lowering, blood fat reducing, to improve the symptom being used for improving metabolic syndrome patients of insulin resistant.
For solving the problems of the technologies described above, the present invention adopts following technical scheme:
In one aspect of the invention, a kind of compositions containing MDG-1 polysaccharide of lilyturf root-1 is provided, mainly be made up of the raw material of following weight portion: MDG-1 polysaccharide of lilyturf root-115-85 part, oligomeric xylose 15-85 part, wherein MDG-1 polysaccharide of lilyturf root-1 is be separated the material of the purified rear molecular weight of total polysaccharides Radix Ophiopogonis obtained below 10,000 dalton medical material from Radix Ophiopogonis.
Be preferably: Radix Ophiopogonis polysaccharide 75 parts, oligomeric xylose 25 parts.
The MDG-1 polysaccharide of lilyturf root-1 that the present invention selects, oligomeric xylose are that structure is different, function is close, stable in physicochemical property, collaborative levan and the oligosaccharide that can produce superposition, thus make said composition have the function of propagation beneficial bacteria of intestinal tract, suppression enteropathogenic bacteria growing.Wherein, oligomeric xylose of the present invention is commercially available prod, and MDG-1 polysaccharide of lilyturf root-1 is separated the material of the purified rear molecular weight of total polysaccharides Radix Ophiopogonis obtained below 10,000 dalton medical material from Radix Ophiopogonis.
Chinese invention patent prospectus CN1445244A(denomination of invention disclosed in the 1 day October in 2003: " MDG-1 polysaccharide of lilyturf root-1 and separation method and application " thereof), describe the preparation method of MDG-1 polysaccharide of lilyturf root-1, the preparation method of the MDG-1 polysaccharide of lilyturf root-1 that the preparation method of MDG-1 polysaccharide of lilyturf root-1 of the present invention is recorded with reference to above-mentioned Chinese invention patent prospectus CN1445244A, specifically comprises the steps:
1) Radix Ophiopogonis total polysaccharides extraction:
Get dry Tubers of Ophiopogon japonicus, with 5-6 times of weight 70%-95% alcohol reflux 3 times, abandon it, medicinal residues water extraction 2-3 time, Aqueous extracts is evaporated to 0.5-1g/ml, add 75%-95% ethanol and reach 60%-80% to alcohol content, hold over night, incline supernatant, and precipitation repeats precipitate with ethanol 1 time, drying, obtains total polysaccharides powder faint yellow Radix Ophiopogonis.
2) ultra-filtration and separation of Radix Ophiopogonis polysaccharide:
By total polysaccharides Radix Ophiopogonis of step 1) gained, dilute with water, 10000 molecular weight membrane ultrafiltration, get small molecular mass moieties, concentrate and obtain Radix Ophiopogonis polysaccharide extract.
3) purification of Radix Ophiopogonis polysaccharide:
Get Radix Ophiopogonis polysaccharide extract, a small amount of water dissolution, upper prop, through water elution, Anthrone-sulfuricacid method on-line checkingi, collect water-wash section peak position, after lyophilization, water dissolution upper prop, water elution, merges peak position, lyophilization, then upper prop, water elution, merges peak position, is MDG-1 polysaccharide of lilyturf root-1.
Conventional pharmaceutical carrier or dressing can be added in the intermediate of the described compositions containing MDG-1 polysaccharide of lilyturf root-1, make the oral formulations of any one common drug or health product.Preferably, described oral formulations is oral liquid, granule, tablet or capsule.
In another aspect of this invention, above-mentioned composition is provided to prepare the application in the medicine or health product improving metabolic syndrome.Described improve metabolic syndrome medicine or health product comprise fat-reducing, blood sugar lowering, blood fat reducing, improve insulin resistant, the medicine of regulating intestinal canal bacterial metabolism or health product.
The present invention utilizes meals inducing obesity (Diet induced Obecity, DIO) mouse model investigates the body weight increase that the composition for improved obesity mice class metabolic syndrome patients containing MDG-1 polysaccharide of lilyturf root-1 of the present invention shows, blood pressure and blood lipoid is disorderly, the symptom such as insulin resistant and intestinal flora imbalance, the compositions of evaluation containing MDG-1 polysaccharide of lilyturf root-1 is to the therapeutical effect of metabolic syndrome.DIO mouse experiment shows, compositions containing MDG-1 polysaccharide of lilyturf root-1 on mice food ration without impact, significantly slowed down in the increase giving compositions Mouse Weight after 4 weeks that optimization contains MDG-1 polysaccharide of lilyturf root-1, blood glucose reduces, serum insulin content alleviates, triglyceride reduces, low close low lipoprotein cholesterol reduces, within every 4 weeks, get animal wastes and do the discovery of external bacteria group culture, the compositions that optimization contains MDG-1 polysaccharide of lilyturf root-1 can suppress escherichia coli, bacteroid growth, promote bacillus bifidus, lactobacillus propagation.This effect continues to experiment in the 12nd week always and terminates.In addition, all the other respectively group compositions administration group Pharmacological Results containing MDG-1 polysaccharide of lilyturf root-1 be also better than independent MDG-1 polysaccharide of lilyturf root-1 group or oligomeric xylose group and model control group.These experimental results are pointed out: the present invention contain the compositions of MDG-1 polysaccharide of lilyturf root-1 by regulating intestinal canal colony balance, reduce blood glucose, reduce blood fat, improve the improved effect metabolic syndrome symptoms such as insulin resistant, can be used for health product or the medicine of preparing corresponding function.
Detailed description of the invention
The invention will be further elaborated by the following examples:
Embodiment 1:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 300g, oligomeric xylose 1700g, then after adding appropriate amount of auxiliary materials, obtained granule one, pack, 1000 bags (every bag containing MDG-1 polysaccharide of lilyturf root-10.25g, oligomeric xylose 1.35g).Adult recommends oral consumption 1 bag/time, every day 2 times.
Embodiment 2:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1000g, oligomeric xylose 1000g, then after adding appropriate amount of auxiliary materials, obtained granule two, pack, 1000 bags (every bag containing MDG-1 polysaccharide of lilyturf root-1 0.8g, oligomeric xylose 0.8g).Adult recommends oral consumption 1 bag/time, every day 2 times.
Embodiment 3:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1500g, oligomeric xylose 500g, then after adding appropriate amount of auxiliary materials, obtained granule three, pack, 1000 bags (every bag containing MDG-1 polysaccharide of lilyturf root-1 1.2g, oligomeric xylose 0.4g).Adult recommends oral consumption 1 bag/time, every day 2 times.
Embodiment 4:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1700g, oligomeric xylose 300g, add appropriate amount of auxiliary materials, obtained granule four, pack, 1000 bags (every bag contains MDG-1 polysaccharide of lilyturf root-1 1.35g, oligomeric xylose 0.25).Adult recommends oral consumption 1 bag/time, every day 2 times.
Embodiment 5:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 300g, oligomeric xylose 1700g, then after adding appropriate amount of auxiliary materials, after pelletizing press sheet, obtained one, 5000, tablet (every sheet is containing MDG-1 polysaccharide of lilyturf root-10.06g, oligomeric xylose 0.3g).Adult recommends oral consumption 3 pieces/times, every day 3 times.
Embodiment 6:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1000g, oligomeric xylose 1000g, then after adding appropriate amount of auxiliary materials, after pelletizing press sheet, obtained two, 5000, tablet (every sheet is containing MDG-1 polysaccharide of lilyturf root-1 0.18g, oligomeric xylose 0.18g).Adult recommends oral consumption 3 pieces/times, every day 3 times.
Embodiment 7:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1500g, oligomeric xylose 500g, then after adding appropriate amount of auxiliary materials, after pelletizing press sheet, obtained three, 5000, tablet (every sheet is containing MDG-1 polysaccharide of lilyturf root-1 0.27g, oligomeric xylose 0.09g).Adult recommends oral consumption 3 pieces/times, every day 3 times.
Embodiment 8:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1700g, oligomeric xylose 300g, add appropriate amount of auxiliary materials, after pelletizing press sheet, obtained four, 5000, tablet (every sheet is containing MDG-1 polysaccharide of lilyturf root-1 0.3g, oligomeric xylose 0.06g).Adult recommends oral consumption 3 pieces/times, every day 3 times.
Embodiment 9:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 300g, oligomeric xylose 1700g, then after adding appropriate amount of auxiliary materials, after granulation, record into capsule one, 5000 (every containing MDG-1 polysaccharide of lilyturf root-1 0.05g, oligomeric xylose 0.27g).Adult recommends oral consumption 3-4 tablet/time, every day 3 times.
Embodiment 10:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1000g, oligomeric xylose 1000g, then after adding appropriate amount of auxiliary materials, after granulation, record into capsule two, 5000 (every containing MDG-1 polysaccharide of lilyturf root-1 0.16g, oligomeric xylose 0.16g).Adult recommends oral consumption 3-4 tablet/time, every day 3 times.
Embodiment 11:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1500g, oligomeric xylose 500g, then after adding appropriate amount of auxiliary materials, after granulation, record into capsule three, 5000 (every containing MDG-1 polysaccharide of lilyturf root-1 0.24g, oligomeric xylose 0.08g).Adult recommends oral consumption 3-4 tablet/time, every day 3 times.
Embodiment 12:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1700g, oligomeric xylose 300g, add appropriate amount of auxiliary materials, after granulation, record into capsule four, 5000 (every containing MDG-1 polysaccharide of lilyturf root-1 0.27g, oligomeric xylose 0.05g).Adult recommends oral consumption 3-4 tablet/time, every day 3 times.
Embodiment 13:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 300g, oligomeric xylose 1700g, then add appropriate amount of auxiliary materials, after distilled water mixing, oral liquid one is made in sterilizing, bottling, and every bottle containing MDG-1 polysaccharide of lilyturf root-1 0.25g, oligomeric xylose 1.35g.Adult recommends oral consumption 1 bottle/time, every day 2 times.
Embodiment 14:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1000g, oligomeric xylose 1000g, then add appropriate amount of auxiliary materials, after distilled water mixing, oral liquid two is made in sterilizing, bottling, and every bottle containing MDG-1 polysaccharide of lilyturf root-1 0.8g, oligomeric xylose 0.8g.Adult recommends oral consumption 1 bottle/time, every day 2 times.
Embodiment 15:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1500g, oligomeric xylose 500g, then add appropriate amount of auxiliary materials, after distilled water mixing, oral liquid three is made in sterilizing, bottling, and every bottle containing MDG-1 polysaccharide of lilyturf root-1 1.2g, oligomeric xylose 0.4g.Adult recommends oral consumption 1 bottle/time, every day 2 times.
Embodiment 16:
Take raw material: MDG-1 polysaccharide of lilyturf root-1 1700g, oligomeric xylose 300g, add appropriate amount of auxiliary materials, after distilled water mixing, oral liquid four is made in sterilizing, bottling, and every bottle containing MDG-1 polysaccharide of lilyturf root-1 1.35g, oligomeric xylose 0.25g.Adult recommends oral consumption 1 bottle/time, every day 2 times.
The pharmacological activity test of the compositions of MDG-1 polysaccharide of lilyturf root-1 and result is contained with the present invention to further illustrate the present invention below by test example.
This test adopts meals obesity-induced mice model to contain the model of the compositions pharmacologically active of MDG-1 polysaccharide of lilyturf root-1 as evaluation the present invention, and EXPERIMENTAL DESIGN is as follows:
1, animal
Select the C57 mice in 4-5 week, male, 200.Rearing conditions: central air-conditioning regulating and controlling temperature and humidity, raises in Mus Special cage tool, 3, every box.Temperature 22 ± 1 DEG C, 40%-60% relative humidity, bright 12 hours of controlled light, dark 12 hours, animal freely ingested and drinks water.
2, medicine and reagent
MDG-1 polysaccharide of lilyturf root-1(makes by oneself, be separated total polysaccharides from Radix Ophiopogonis and obtain, its separation method is open on October 1st, 2003 see Chinese invention patent prospectus CN1445244A(, and denomination of invention is: " MDG-1 polysaccharide of lilyturf root-1 and separation method and application " thereof); Oligomeric xylose (food-grade xylooligosaccharide, purchased from Hebi City Tai Xin Science and Technology Ltd.); Normal diet (purchased from Shanghai Slac Experimental Animal Co., Ltd.); High lipid food (60% fatty amount, D12492, purchased from American Research Diet company); Mouse islets element (EXRMI-13K); Triglyceride, T-CHOL, high density lipoprotein and low density lipoprotein, LDL assay kit are purchased from Roche Diagnostics company (Mannheim, Germany); Sodium chloride injection (purchased from Shijiazhuang Siyao Co., Ltd); The steady person of outstanding talent of ONE TOUCH doubly easy reagent paper (Johnson Co.).
3, experimental technique
3.1 abdominal obesity mice modelings
Blank group C57 mice feeds with normal diet.Other C57 mices all feed with high lipid food, freely enter to take the photograph water food.When mice was fed to 8 weeks, according to Mouse Weight by mice group, make each group of body weight consistent, often organize 12.From the 8th week, animal was by grouping to respective reagent, and model group and blank group gavage equal-volume normal saline, amounts to 12 weeks.Every 2 weeks of period detected animal Stochastic sum fasting glucose and body weight change, within every 4 weeks, detect animal serum insulin level, before experiment starts and at the end of (the 0th week and the 12nd week) detection animal total triglyceride, T-CHOL, low-density lipoprotein cholesterol level, and get animal fresh excreta, external bacteria group culture detects its proliferation function to escherichia coli, bacteroid, lactobacillus, bacillus bifidus.
3.2 laboratory animal packet design
Get after respective tablets, granule and capsule (embodiment 1,5,9) dissolve and be made into compositions one, (corresponding concentration is 52mg/kg MDG-1 polysaccharide of lilyturf root-1 and 300mg/kg oligomeric xylose), the compositions one (i.e. MDG-1 polysaccharide of lilyturf root-115 parts, oligomeric xylose 85 parts) of corresponding concentration is made into after oral liquid (embodiment 13) is concentrated; Separately get after respective tablets, granule and capsule (embodiment 2,6,10) dissolve and be made into compositions two (corresponding concentration is 300mg/kg MDG-1 polysaccharide of lilyturf root-1 and 300mg/kg oligomeric xylose), the compositions two (i.e. MDG-1 polysaccharide of lilyturf root-150 parts, oligomeric xylose 50 parts) of corresponding concentration is made into after oral liquid (embodiment 14) is concentrated; Separately get after respective tablets, granule and capsule (embodiment 3,7,11) dissolve and be made into compositions three (corresponding concentration is 300mg/kg MDG-1 polysaccharide of lilyturf root-1 and 100mg/kg oligomeric xylose), the compositions three (i.e. MDG-1 polysaccharide of lilyturf root-1 75 part, oligomeric xylose 25 parts) of corresponding concentration is made into after oral liquid (embodiment 15) is concentrated; Get after respective tablets, granule and capsule (embodiment 4,8,12) dissolve and be made into compositions four (corresponding concentration is 300mg/kg MDG-1 polysaccharide of lilyturf root-1 and 52mg/kg oligomeric xylose), the compositions four (i.e. MDG-1 polysaccharide of lilyturf root-1 85 part, oligomeric xylose 15 parts) of corresponding concentration is made into after oral liquid (embodiment 16) is concentrated.
Laboratory animal is divided into blank group (gavaging normal saline), model group (gavaging normal saline), 52mg/kg MDG-1 group, 300mg/kg MDG-1 group, 52mg/kg oligomeric xylose group, 100mg/kg oligomeric xylose group, 300mg/kg oligomeric xylose group, compositions one group, compositions two groups, compositions three groups, compositions four groups.
Test example 1: the impact that meals inducing obesity (DIO) Mouse Weight is increased
The 9:00 in morning Tuesday of every 2 weeks records the weight of animals, and result is as table 1.
Table 1. on the impact of DIO Mouse Weight (body weight value, g, n=12,
)
Note: compare with model group
*, P ﹤ 0.05;
*, P ﹤ 0.001
Result is pointed out: 4 compositions groups all can reduce Mouse Weight, and wherein compositions three groups of effects are particularly evident.The effect that compositions is three groups considerably beyond the effect of MDG-1 group and oligomeric xylose group, will embody the synergism that MDG-1 polysaccharide of lilyturf root-1 and oligomeric xylose two combination of components produce by the present invention.
Test example 2: on the impact of DIO mice random blood sugar and fasting glucose
Each treated animal gets hematometry random blood sugar, fasting subsequently 6 hours in the first day 9:00am tail point of every 2 weeks, and 15:00pm measures fasting glucose.
Experimental result as Table 2,3.
Table 2. on the impact of DIO mice random blood sugar (blood glucose value, mmol/L, n=12,
)
Note: compare with model group
*, P ﹤ 0.05;
*, P ﹤ 0.001
Table 3. on the impact of DIO mice fasting glucose (blood glucose value, mmol/L, n=12,
)
Note: compare with model group
*, P ﹤ 0.05;
*, P ﹤ 0.001
Result is pointed out: 300mg/kg MDG-1 polysaccharide of lilyturf root-1 group and 4 compositions groups all can reduce mice Stochastic sum fasting glucose, and wherein compositions three groups of effects are particularly evident.The effect that compositions is three groups considerably beyond the effect of MDG-1 group and oligomeric xylose group, will embody the synergism that MDG-1 polysaccharide of lilyturf root-1 and oligomeric xylose two combination of components produce by the present invention.
Test example 3 is on the impact of DIO mice serum insulin level
Every 4 weeks of each treated animal in the morning Wednesday 9:00 eye socket get blood, 4000rpm centrifuging and taking serum, for measuring serum insulin levels.The results are shown in Table 4.
Table 4. on the impact of DIO mice serum insulin level (insulin, ng/mL, n=12,
)
Note: compare with model group
*, P ﹤ 0.05;
*, P ﹤ 0.001
Result is pointed out: 300mg/kg MDG-1 polysaccharide of lilyturf root-1 group and 4 compositions groups all can reduce mice serum insulin level, and wherein compositions three groups of effects are particularly evident.The effect that compositions is three groups considerably beyond the effect of MDG-1 group and oligomeric xylose group, will embody the synergism that MDG-1 polysaccharide of lilyturf root-1 and oligomeric xylose two combination of components produce by the present invention.
Test example 4 is on the impact of DIO lipid of mice level
Each treated animal in experiment the 0th week and the 12nd week all 4 the morning 9:00 eye socket get blood, measure the total triglyceride of blood plasma, T-CHOL, low-density lipoprotein cholesterol level after separated plasma.The results are shown in Table 5.
Table 5. on the impact of DIO mice plasma blood lipid level (mM, n=12,
)
Note: compare with model group
*, P ﹤ 0.05;
*, P ﹤ 0.001
Result is pointed out: 300mg/kg MDG-1 polysaccharide of lilyturf root-1 group, each concentration oligomeric xylose group and 4 compositions groups have impact to the total triglyceride of mice and total cholesterol level, 300mg/kg oligomeric xylose group and 4 compositions groups can reduce the low close low lipoprotein cholesterol of mice, and wherein compositions three groups of effects are the most obvious.The effect that compositions is three groups considerably beyond the effect of MDG-1 group and oligomeric xylose group, will embody the synergism that MDG-1 polysaccharide of lilyturf root-1 and oligomeric xylose two combination of components produce by the present invention.
Test example 5: on the impact of DIO mouse intestinal flora metabolism
Each treated animal in the 0th week and the 12nd week morning Tuesday 9:00-12:00 move in metabolic cage, collect fresh excreta, carry out intestinal microbial population detection (comprising escherichia coli, lactobacillus, bacillus bifidus and bacteroid).The results are shown in Table 6.
Table 6. is on the impact (Log of DIO mouse intestinal flora content
cFU/g, n=12,
)
Note: compare with model group
*, P ﹤ 0.05;
*, P ﹤ 0.001
Result is pointed out: 4 compositions groups all can regulate microbial population of animal intestinal tract content in various degree, and wherein compositions three groups of effects are the most remarkable.The effect that compositions is three groups considerably beyond the effect of MDG-1 group and oligomeric xylose group, will embody the synergism that MDG-1 polysaccharide of lilyturf root-1 and oligomeric xylose two combination of components produce by the present invention.
Claims (4)
1. the compositions containing MDG-1 polysaccharide of lilyturf root-1, it is characterized in that, said composition is mainly made up of the raw material of following weight portion: MDG-1 polysaccharide of lilyturf root-175 parts, oligomeric xylose 25 parts, wherein MDG-1 polysaccharide of lilyturf root-1 is be separated the material of the purified rear molecular weight of total polysaccharides Radix Ophiopogonis obtained below 10,000 dalton medical material from Radix Ophiopogonis; Described MDG-1 polysaccharide of lilyturf root-1 is adopted and is obtained with the following method:
1) Radix Ophiopogonis total polysaccharides extraction:
Get dry Tubers of Ophiopogon japonicus, with 5-6 times of weight 70%-95% alcohol reflux 3 times, abandon it, medicinal residues water extraction 2-3 time, Aqueous extracts is evaporated to 0.5-1g/ml, add 75%-95% ethanol and reach 60%-80% to alcohol content, hold over night, incline supernatant, and precipitation repeats precipitate with ethanol 1 time, drying, obtains total polysaccharides powder faint yellow Radix Ophiopogonis;
2) ultra-filtration and separation of Radix Ophiopogonis polysaccharide:
By step 1) total polysaccharides Radix Ophiopogonis of gained, dilute with water, 10000 molecular weight membrane ultrafiltration, get small molecular mass moieties, concentrate and obtain Radix Ophiopogonis polysaccharide extract;
3) purification of Radix Ophiopogonis polysaccharide:
Get Radix Ophiopogonis polysaccharide extract, a small amount of water dissolution, upper prop, through water elution, anthrone-sulfuric acid process on-line checkingi, collect water-wash section peak position, after lyophilization, water dissolution upper prop, water elution, merges peak position, lyophilization, then upper prop, water elution, merges peak position, is MDG-1 polysaccharide of lilyturf root-1.
2. compositions as claimed in claim 1, is characterized in that, add pharmaceutical carrier or dressing in the composition, make the oral formulations of medicine or health product.
3. compositions as claimed in claim 2, it is characterized in that, described oral formulations is oral liquid, granule, tablet or capsule.
4. the compositions as described in any one of claim 1-3 is in preparation fat-reducing, blood sugar lowering, blood fat reducing, the application improved in insulin resistant, the medicine of regulating intestinal canal bacterial metabolism or health product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310437140.0A CN103520200B (en) | 2013-09-24 | 2013-09-24 | Compositions containing MDG-1 polysaccharide of lilyturf root-1 and improve the application in the medicine of metabolic syndrome or health product in preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310437140.0A CN103520200B (en) | 2013-09-24 | 2013-09-24 | Compositions containing MDG-1 polysaccharide of lilyturf root-1 and improve the application in the medicine of metabolic syndrome or health product in preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103520200A CN103520200A (en) | 2014-01-22 |
| CN103520200B true CN103520200B (en) | 2015-07-29 |
Family
ID=49922788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310437140.0A Expired - Fee Related CN103520200B (en) | 2013-09-24 | 2013-09-24 | Compositions containing MDG-1 polysaccharide of lilyturf root-1 and improve the application in the medicine of metabolic syndrome or health product in preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103520200B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110964126A (en) * | 2019-12-24 | 2020-04-07 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Radix ophiopogonis degradation extract and application thereof in preparation of cardiovascular disease prevention and treatment medicines |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1445244A (en) * | 2003-03-11 | 2003-10-01 | 上海中医药大学附属曙光医院 | Lilyturf root polysaccharide MDG-1 and its separation method and application |
| CN101564399A (en) * | 2008-04-23 | 2009-10-28 | 上海中医药大学 | Application of ophiopogonpolysaccharide MDG-1 in preparing medicament for treating diabetes mellitus |
| CN102757508A (en) * | 2011-04-25 | 2012-10-31 | 上海张江中药现代制剂技术工程研究中心 | Application of ophiopogon polysaccharide extract in preparing foodstuff additives, health-care products or medicines with weight-reducing function |
-
2013
- 2013-09-24 CN CN201310437140.0A patent/CN103520200B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1445244A (en) * | 2003-03-11 | 2003-10-01 | 上海中医药大学附属曙光医院 | Lilyturf root polysaccharide MDG-1 and its separation method and application |
| CN101564399A (en) * | 2008-04-23 | 2009-10-28 | 上海中医药大学 | Application of ophiopogonpolysaccharide MDG-1 in preparing medicament for treating diabetes mellitus |
| CN102757508A (en) * | 2011-04-25 | 2012-10-31 | 上海张江中药现代制剂技术工程研究中心 | Application of ophiopogon polysaccharide extract in preparing foodstuff additives, health-care products or medicines with weight-reducing function |
Non-Patent Citations (1)
| Title |
|---|
| 低聚木糖的研究进展;吴学敏等;《贵阳中医学院学报》;20130531;第26页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103520200A (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101822749B (en) | Medicinal preparation for curing hypertension and hyperlipaemia and preparation method thereof | |
| CN102757508A (en) | Application of ophiopogon polysaccharide extract in preparing foodstuff additives, health-care products or medicines with weight-reducing function | |
| CN106721803A (en) | A kind of selenium-rich health-care salicorne beverage | |
| CN109010616A (en) | A kind of pure plant preparation for increasing beneficial bacteria of intestinal tract, improving intestinal flora | |
| CN102578668B (en) | Beverage for assisting in reducing blood sugar | |
| CN105031197B (en) | A kind of Chinese medicine composition and the preparation method and application thereof with throat soothing function of moistening and cleaning throat | |
| CN101390923A (en) | Preparation method of gadol polyferose composite formaulation and use thereof | |
| CN101744844B (en) | Fulvic acid or sodium fulvate substance with hypoglycemic function | |
| CN110313599A (en) | A kind of anti-trioxypurine jelly and preparation method thereof | |
| CN103520200B (en) | Compositions containing MDG-1 polysaccharide of lilyturf root-1 and improve the application in the medicine of metabolic syndrome or health product in preparation | |
| CN1985917B (en) | Medicine composition for reducing blood sugar, reducing blood fat and controlling diabetes complication | |
| CN103750096B (en) | Propolis honey being rich in plant essence and preparation method thereof | |
| CN105708934A (en) | Composition capable of stabilizing blood glucose and reducing blood glucose and preparation process thereof | |
| CN102669345A (en) | Brain nourishing nutrition food of brain nourishing tea granule | |
| CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
| CN102784230B (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN104644734A (en) | Drug for treating type II diabetes and complications thereof | |
| CN103920140A (en) | Compound preparation for reducing blood glucose, body weight and fat for human | |
| CN104189038B (en) | Chinese medicine preparation for nursing one's health female pathology health and immunologic function | |
| CN116268414A (en) | Composition for improving gastrointestinal function and preventing constipation and application thereof | |
| CN102949681B (en) | Composition for preventing or treating colds, and its preparation method | |
| CN106109951A (en) | Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof | |
| CN100438899C (en) | Medicine for treating diabetes and its preparing method | |
| CN101468056B (en) | Chinese medicine preparation for treating enteritis, diarrhea, and red-white dysentery | |
| CN111265627B (en) | Sea cucumber polysaccharide composition for regulating intestinal flora and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150729 Termination date: 20190924 |